Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

QR Code

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd L. Gammelgaard, Monique F. Hundebøl, Kamila Kaminska, Lene E. Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik J. Ditzel
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2021
Sujets:	Science Q
Accès en ligne:	https://doaj.org/article/df7e78eab9c643b4bcc917eea8a3ff30
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
par: Carla L. Alves, et autres
Publié: (2021)

Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
par: Olga Martínez-Sáez, et autres
Publié: (2021)

Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2− Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies
par: Abeer J. Al-Qasem, et autres
Publié: (2021)

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
par: Lindsey R. Pack, et autres
Publié: (2021)

Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
par: Erin R. Scheidemann, et autres
Publié: (2021)

SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
par: Yibo Xue, et autres
Publié: (2019)

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
par: Luigi Formisano, et autres
Publié: (2019)

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
par: Jennifer Y. Ge, et autres
Publié: (2020)

The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
par: Emily Jiggens, et autres
Publié: (2021)

Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
par: Fabin Dang, et autres
Publié: (2021)

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
par: Iorfida M, et autres
Publié: (2020)

CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma
par: Jin Zhou, et autres
Publié: (2017)

CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1
par: Tongzheng Liu, et autres
Publié: (2017)

Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice
par: Irina V. Kolyadina, et autres
Publié: (2021)

Učinkovitost in najpogostejši neželeni učinki zdravljenja z zaviralci od ciklina odvisnih kinaz 4 in 6 (CDK 4/6) pri metastatskem raku dojke
par: Nina Privšek, et autres
Publié: (2021)

Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma
par: Shuo Qie, et autres
Publié: (2019)

A Cdk4/6-dependent phosphorylation gradient regulates the early to late G1 phase transition
par: Manuel Kaulich, et autres
Publié: (2021)

Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment
par: Ying Ji, et autres
Publié: (2020)

Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
par: Board Editorial
Publié: (2021)

CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary
par: Yibo Xue, et autres
Publié: (2019)

Association of Endocrine Therapy and Dementia in Women with Breast Cancer
par: Thompson MR, et autres
Publié: (2021)

Metastatic breast cancer: Endocrine therapy landscape reshaped
par: Mohamad Adham Salkeni, et autres
Publié: (2017)

Estrogen Receptors as Molecular Targets of Endocrine Therapy for Glioblastoma
par: Andrea Magali González-Mora, et autres
Publié: (2021)

Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency.
par: Grzegorz Sarek, et autres
Publié: (2010)

CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines.
par: Gabriela M Wright, et autres
Publié: (2021)

Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4/6 inhibition
par: Lauren E. Stopfer, et autres
Publié: (2020)

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
par: Smruthi Vijayaraghavan, et autres
Publié: (2017)

Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer
par: Jingyi Liu, et autres
Publié: (2018)

LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway
par: Ang Gao, et autres
Publié: (2018)

IgG4-related disease in endocrine practice
par: Agata Rzepecka, et autres
Publié: (2018)

CDK6 inhibits white to beige fat transition by suppressing RUNX1
par: Xiaoli Hou, et autres
Publié: (2018)

Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy
par: Sung Pil Hong, et autres
Publié: (2019)

Endocrine today

Endocrine research
Publié: (1984)

Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer
par: Qingfei Wang, et autres
Publié: (2019)

Fascaplysin as a specific inhibitor for CDK4: insights from molecular modelling.
par: Muhammad Imtiaz Shafiq, et autres
Publié: (2012)

Silencing CDK6-AS1 inhibits LPS-induced inflammatory damage in HK-2 cells
par: Wu Ling, et autres
Publié: (2021)

Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes
par: Mikkel G. Terp, et autres
Publié: (2021)

Three decades of Cdk5
par: Ping-Chieh Pao, et autres
Publié: (2021)

BMC endocrine disorders
Publié: (2001)